pf-07264660
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 16, 2022 (NCT05496738)
Timeline
Indications
Mechanism of action
- Interferon betaINHIBITOR
inhibitor - IFNB1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06712082 | Phase 1 | Feb 28, 2025 | Pfizer |
| NCT05995964 | Phase 2 | Aug 22, 2023 | Pfizer |
| NCT05496738 | Phase 1 | Aug 16, 2022 | Pfizer |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 3 | 3 | 2 | 2022 |
1 organizations
Page 1 / 1